InfectRisk

Flu season in Belgium

Current flu, COVID-19 and RSV activity in Belgium, based on ECDC ERVISS weekly data from Sciensano. Rescaled into a consultation-equivalent signal for a qualitative low / moderate / high classification.

Influenza: Low

Low

The source currently reports no meaningful activity (as of 16 Aug 2026).

Data window: Week 33 · Aug 10 – Aug 16 · Source: ECDC (weekly) · Source on seasonal break, next data from week 40

Get one free alert when the wave turns in Belgium

We write exactly once: the moment the level goes up. No account, no newsletter. We store your address and the country, nothing else. Every mail has a one click unsubscribe. Privacy

View the last 8 weeks

In week 33 of 2026, Influenza activity in Belgium is classified as low.

The source reports no meaningful activity across these weeks; a week-over-week percentage would be pure noise here.

The last 8 reported weeks

WeekRelativeLevelvs prior week
Week 33Low
Week 32Low
Week 31Low
Week 30Low
Week 29Low
Week 28Low
Week 27Low
Week 26Low

Across these weeks the source reports no meaningful activity, the values sit at the floor of its scale.

Is flu going around right now?

Know when it affects you.

This page shows your country. The app shows you.

  • Exact numbers and incidence rates, not just low, moderate, high
  • Your personal risk by age and region
  • A push alert when the wave tips in your region
  • 35 countries and a home-screen widget
Download on the

Current activity

12-week trend · Influenza · Relative development · ECDC ERVISS
Week 22Week 25Week 28Week 30Week 33
  • InfluenzaLow
    Trend: stable · Week 33
  • COVID-19Low
    Trend: stable · Week 33
  • RSVLow
    Trend: stable · Week 33

What this means

In week 33 of 2026, activity of influenza (seasonal flu) in Belgium is low. The trend, derived from clinical surveillance, is stable.

Data, context and methodology

The current picture for Belgium is built on the European Respiratory Virus Surveillance Summary (ERVISS), published weekly by the European Centre for Disease Prevention and Control (ECDC). Sciensano via its sentinel GP network and the National Reference Centre for Influenza is the national public-health authority that feeds ERVISS with sentinel primary care and virology data.

ECDC ERVISS

ERVISS is ECDC's weekly pan-European surveillance summary for influenza, SARS-CoV-2 and RSV. National authorities, in Belgium's case Sciensano via its sentinel GP network and the National Reference Centre for Influenza, submit harmonised indicators every week, which ECDC publishes in a standardised dataset on Thursdays. Using ERVISS rather than each country's native portal ensures cross-country comparability.

ILI / ARI consultation rates and positivity

Sciensano via its sentinel GP network and the National Reference Centre for Influenza operates a sentinel network of general practices that report weekly rates of patients consulting for influenza-like illness (ILI) or acute respiratory infection (ARI). A subset of patients is swabbed and tested by reference laboratories, producing pathogen-specific positivity rates for flu, SARS-CoV-2 and RSV.

Why this source

Combining consultation incidence with virological positivity yields a pathogen-specific weekly incidence signal (ILI × positivity / 100). This is the standard European methodology and provides a more robust view than either indicator alone: consultation rates capture illness burden, positivity confirms which pathogen is driving it.

Qualitative classification

The “low”, “moderate” and “high” categories follow seasonal reference values and epidemiological thresholds calibrated to match our classifications for other countries. The ILI × positivity / 100 product is scaled to comparable thresholds using a divisor of 3, which aligns European sentinel peaks with the consultation-equivalent scale used elsewhere. Data refreshes weekly when ECDC publishes the latest ERVISS update, typically on Thursdays.

Source and seasonal pattern by pathogen

Influenza
The classification is based on the ECDC ERVISS weekly reports, drawing on data from Sciensano via its sentinel GP network and the National Reference Centre for Influenza. Seasonally, infection waves in Belgium typically peak between December and February; activity is usually markedly lower during the summer months.
COVID-19
The classification is based on the ECDC ERVISS weekly reports, drawing on COVID-19 surveillance data from Sciensano via its sentinel GP network and the National Reference Centre for Influenza. Seasonally, infection waves in Belgium typically peak during winter, with occasional summer waves driven by new variants; activity is usually markedly lower in late spring between waves.
RSV
The classification is based on the ECDC ERVISS weekly reports, drawing on RSV surveillance data from Sciensano via its sentinel GP network and the National Reference Centre for Influenza. Seasonally, infection waves in Belgium typically peak between December and February; activity is usually markedly lower in spring and summer.

Frequently asked questions

When is flu season in Belgium?

Belgian flu activity usually builds through December, peaks between December and February, and eases by April. Timing and intensity depend on the dominant influenza subtypes and residual immunity. Sciensano, Belgium's national public-health institute in Brussels, publishes weekly influenza updates describing the season in qualitative phases rather than precise onset dates.

How does Sciensano classify flu severity?

Sciensano classifies flu activity in qualitative bands (baseline, low, moderate, high, very high) drawing on its sentinel GP network, sentinel laboratories, and hospital surveillance for severe acute respiratory infection. Each week's classification is compared with historical reference ranges. Sciensano also transmits Belgian indicators to ECDC ERVISS, which places them alongside other EU/EEA countries using harmonised tiering.

How is flu surveillance organised in Belgium?

Belgian flu surveillance combines a sentinel network of general practitioners reporting weekly influenza-like illness consultations, sentinel laboratories testing respiratory samples for influenza subtypes, and hospital surveillance of severe acute respiratory infection. The National Reference Centre for Influenza, hosted at Sciensano, performs virological characterisation. Results feed Sciensano's weekly respiratory-virus bulletin and ECDC ERVISS.

Is the flu vaccine reimbursed in Belgium?

Belgium's Conseil Supérieur de la Santé / Hoge Gezondheidsraad recommends annual flu vaccination for priority groups including adults aged 65 and above, pregnant women, people with chronic conditions, residents of long-term-care facilities, and healthcare workers. The vaccine is partially reimbursed by the INAMI/RIZIV for these groups. Sciensano publishes vaccination-coverage estimates alongside its weekly flu surveillance.

How does Belgium compare to its European neighbours?

Because Belgium reports into ECDC ERVISS with harmonised indicators, its weekly flu classification is directly comparable with France, the Netherlands, Luxembourg, and the rest of the EU/EEA. Belgium sometimes sees flu activity pick up slightly earlier than its western European neighbours, though lead–lag differences of a few weeks are typical and visible in ECDC's dashboards.

More situation reports

ECDC ERVISSECDC DataUpdated: Aug 31, 2026, 11:10
Published by Dominik Martin · Software engineer and data aggregator· Methodology last reviewed: 07 May 2026· Methodology version 1.2

Data last refreshed: Aug 31, 2026, 11:10. Update cadence: weekly.

This page is not medical advice and does not replace consultation with a healthcare professional. For specific symptoms, please contact a medical professional.

About this page

Published by Renderei Martin GmbH, Berlin. No commercial interest in individual health recommendations. The app is optionally monetised via a freemium subscription.

Content is based exclusively on the linked official surveillance publications. Medical statements are curated against the guidance of RKI, ECDC and WHO.

Methodology enquiries: press@infectrisk.com

About this site and its author